Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Second Sight Medical Products, Inc. (NASDAQ: EYES).

Full DD Report for EYES

You must become a subscriber to view this report.


Recent News from (NASDAQ: EYES)

Second Sight Medical Products, Inc. to Present at the 19th Annual B. Riley FBR Investor Conference
Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Will McGuire, President and C...
Source: Business Wire
Date: May, 14 2018 08:00
Second Sight Medical Products: Q1 Implant Results Disappoint
Q1 Implant Results: Disappointing Q1 Argus II implant results came in at a weak 16 units , down from 30 units in the 4th quarter. As a result, revenue was down to $976k vs $3.1mil in Q4. As you can see here in our EYES corporate overview, after 100% revenue growth in 2017, we suspect ...
Source: SeekingAlpha
Date: May, 11 2018 09:59
Second Sight Medical Products' (EYES) CEO Will McGuire on Q1 2018 Results - Earnings Call Transcript
Second Sight Medical Products (EYES) Q1 2018 Earnings Conference Call May 10, 2018 04:30 PM ET Executives Lisa Wilson - IR Will McGuire - President and CEO John Blake - CFO Analysts Dallas Salazar - Atlas Consulting Amit Dayal - H. C. Wainwright & Co Presentation ...
Source: SeekingAlpha
Date: May, 10 2018 22:15
Second Sight Reports First Quarter 2018 Financial Results
--Orion Feasibility Study on Track with Encouraging Early Results and Four of Five Subjects Implanted -- -- Completed Private Placement of $10 million -- Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, ...
Source: Business Wire
Date: May, 10 2018 16:01
Second Sight Medical Products: Riding The Cash Roller Coaster To Nowhere
Second Sight Medical Products, Inc. (NASDAQ: EYES ) is a manufacturer of prosthetic devices for the blind. The company’s primary product is the Argus II System for the treatment of Retinitis Pigmentosa (NASDAQ: RP ), a hereditary disease that causes tunnel vision and eventually leads ...
Source: SeekingAlpha
Date: May, 10 2018 13:25
Daily Insider Ratings Round Up 5/7/18: TSLA, TEGP, CVS, NHF, FLDM, AKAO, EYES, MDB
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: May, 09 2018 09:36
Second Sight Completes $10 Million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors
Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that it has entered into a stock p...
Source: Business Wire
Date: May, 07 2018 08:00
Second Sight to Discuss First Quarter 2018 Financial Results on May 10, 2018 Conference Call
Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind patients, will release its 2018 first quarter financial results on Thursday, May 10, 2018, af...
Source: Business Wire
Date: May, 03 2018 17:00
Research Report Identifies Flexsteel Industries, Second Sight Medical Products, XG Technology, CRA International, Inc, Neos Therapeutics, and Tech Data with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Flexsteel Industries, Inc. (NASDAQ:FLXS), Second Sight Medical Products, I...
Source: GlobeNewswire
Date: May, 01 2018 08:10
Second Sight Announces Dr. Robert Greenberg's Resignation from Board of Directors and as an Officer of the Company
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Dr. Robert Greenberg, MD, PhD ...
Source: Business Wire
Date: April, 09 2018 16:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-171.551.54731.601.54109,233
2018-08-161.601.551.60871.52144,633
2018-08-151.581.5051.581.50154,764
2018-08-141.501.561.591.50100,948
2018-08-131.621.551.62011.5584,280

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1735,54144,48779.8908Short
2018-08-1626,01734,13876.2113Short
2018-08-1515,70747,64532.9667Cover
2018-08-1411,04230,52336.1760Short
2018-08-1312,09837,88131.9369Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EYES.


About Second Sight Medical Products, Inc. (NASDAQ: EYES)

Logo for Second Sight Medical Products, Inc. (NASDAQ: EYES)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $122,745,220 - 05/16/2018
    • Authorized: 200,000,000 - 05/01/2018
    • Issue and Outstanding: 59,875,717 - 05/01/2018

     


    Recent Filings from (NASDAQ: EYES)

    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 15 2018
    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: May, 14 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 11 2018
    Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
    Filing Type: DFiling Source: edgar
    Filing Date: May, 08 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 08 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 01 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 13 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 09 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 27 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 20 2018

     

     


    Daily Technical Chart for (NASDAQ: EYES)

    Daily Technical Chart for (NASDAQ: EYES)


    Stay tuned for daily updates and more on (NASDAQ: EYES)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: EYES)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EYES is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EYES and does not buy, sell, or trade any shares of EYES. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/